Spots Global Cancer Trial Database for Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer

Official Title: 64Cu-DOTA-B-Fab as A PET Tracer for Evaluating CA6 Expression in Tumors: A First in Human Study

Study ID: NCT02708511

Conditions

Ovarian Carcinoma

Breast Carcinoma

Interventions

Computed Tomography

Copper Cu 64-DOTA B-Fab

Laboratory Biomarker Analysis

Pharmacological Study

Positron Emission Tomography

Study Description

Brief Summary: This pilot clinical trial studies copper Cu 64-DOTA-B-Fab positron emission tomography (PET)/computed tomography (CT) in imaging patients with ovarian and breast cancer. Cancer antigen (CA)6 is an antigen (substance) found on the surface of several types of cancer cells such as cancer of the ovary and breast. Diagnostic procedures, such as copper Cu 64-DOTA-B-Fab PET/CT, may help identify CA6 positive tumors and allow doctors to plan better treatment.

Detailed Description: PRIMARY OBJECTIVES: I. To determine the dosimetry of 64Cu-DOTA B-Fab (copper Cu 64-DOTA-B-Fab). SECONDARY OBJECTIVES: I. To evaluate the safety of 64Cu-DOTA B-Fab single administration. II. To evaluate the ability of 64Cu-DOTA B-Fab to detect CA6-positive ovarian and breast cancer lesions. III. To compare PET results with the immunohistochemistry (IHC) analysis of the excised tumor samples. OUTLINE: Patients receive copper Cu 64-DOTA-B-Fab intravenously (IV) followed by PET/CT 60 minutes post-injection and 24 hours post-injection After completion of study, patients are followed up for 12 months.